title: Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression.
abstract: Accumulating evidence suggests that inflammatory processes are involved in the development of diabetic nephropathy (DN). However, there are no effective interventions for inflammation in the diabetic kidneys. Here, we tested the hypothesis that Astragaloside IV(AS-IV), a novel saponin purified from Astragalus membranaceus (Fisch) Bge, ameliorates DN in streptozotocin (STZ)-induced diabetic rats through anti-inflammatory mechanisms. Diabetes was induced with STZ (65 mg/kg) by intraperitoneal injection in rats. Two weeks after STZ injection, rats were divided into three groups (n=8/each group), namely, diabetic rats, diabetic rats treated with AS-IV at 5 and 10 mgkg(-1)d(-1), p.o., for 8 weeks. The normal rats were chosen as nondiabetic control group (n=8). The rats were sacrificed 10 weeks after induction of diabetes. AS-IV ameliorated albuminuria, renal histopathology and podocyte foot process effacement in diabetic rats. Renal NF-κB activity, as wells as protein and mRNA expression were increased in diabetic kidneys, accompanied by an increase in mRNA expression and protein content of TNF-α, MCP-1 and ICAM-1 in kidney tissues. The α1-chain type IV collagen mRNA was elevated in the kidneys of diabetic rats. All of these abnormalities were partially restored by AS-IV. AS-IV also decreased the serum levels of TNF-α, MCP-1 and ICAM-1 in diabetic rats. These findings suggest that AS-IV, a novel anti-inflammatory agent, attenuated DN in rats through inhibiting NF-κB mediated inflammatory genes expression.
authors: Department of Nephrology and Rheumatology, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, PR China.
authors: Dingkun
authors: D
authors: Gui
authors: Jianhua
authors: J
authors: Huang
authors: Yongping
authors: Y
authors: Guo
authors: Jianguo
authors: J
authors: Chen
authors: Yifang
authors: Y
authors: Chen
authors: Wenzhen
authors: W
authors: Xiao
authors: Xusheng
authors: X
authors: Liu
authors: Niansong
authors: N
authors: Wang
mesh_terms: D000419:Albuminuria / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D000818:Animals; D015415:Biomarkers / Q000097:blood; D018932:Chemokine CCL2 / Q000097:blood / Q000235:genetics; D024141:Collagen Type IV / Q000235:genetics / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D005786:Gene Expression Regulation / Q000187:drug effects; D007249:Inflammation / Q000097:blood / Q000150:complications / Q000235:genetics*; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood / Q000235:genetics; D007674:Kidney Diseases / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D016328:NF-kappa B / Q000378:metabolism*; D050199:Podocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology / Q000648:ultrastructure; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012503:Saponins / Q000494:pharmacology / Q000627:therapeutic use*; D014315:Triterpenes / Q000494:pharmacology / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000235:genetics
chemical_list: D015415:Biomarkers; D018932:Chemokine CCL2; D024141:Collagen Type IV; D016328:NF-kappa B; D012333:RNA, Messenger; D012503:Saponins; D014315:Triterpenes; D014409:Tumor Necrosis Factor-alpha; D018799:Intercellular Adhesion Molecule-1; C052064:astragaloside A